Avalyn Pharma Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Avalyn Pharma Inc. (AVLN) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 7.08 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-12
- Avalyn Pharma Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 28.51M shares, a 35.08% increase year-over-year.
- Avalyn Pharma Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 21.11M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month |
|---|---|---|
| 2026-06-30 | 7.08M shares 10-Q · filed 2026-08-12 | |
| 2026-03-31 | 28.51M shares 10-Q · filed 2026-06-03 | |
| 2025-06-30 | 26.37M shares 10-Q · filed 2026-08-12 | |
| 2025-03-31 | 21.11M shares 10-Q · filed 2026-06-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B |